Viking Therapeutics, Inc. (VKTX) Stock Analysis — Probabli.AI
AI-powered analysis for VKTX (Viking Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $32.98 · Market cap: $3.7B · AI outlook: Bullish
Viking Therapeutics demonstrates high potential in the biopharmaceutical sector, particularly through its flagship VK2809, with strong advances in clinical trials. Analyst sentiment, significant pipeline opportunities, and projected milestones make this a compelling investment, albeit with substantial competitive and financial risks. Mixed near-term developments are outweighed by long-term growth…
Probabilistic 1-Year Outlook
- Bull 40% · Neutral 45% · Bear 15%
- 1-year price estimates — P10: $26 / P50: $45 / P90: $100
- Viking Therapeutics has strong potential backed by positive drug development updates, analyst confidence with highly elevated price targets, and meaningful strides in advancing VK2809. However, it faces execution risks,…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $35 / P50: $130 / P90: $300
SWOT Highlights
- Strength: Strong pipeline with VK2809 showing promising results.
- Strength: Analyst consensus implies significant upside potential.
- Risk: Negative average EPS surprise indicates possible forecasting or execution issues.
- Risk: Cash burn rate exhibits financial strain concerns.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate VKTX a BUY with a mean price target of $88.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
VKTX forecast details · VKTX sentiment details · VKTX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.